Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsRumi Advances PDE2 Inhibitor RTX-7340 for Fragile X SyndromeRumi Therapeutics has secured an option-to-license agreement with Enthorin Therapeutics for RTX-7340, an investigational PDE2 inhibitor supported by preclinical findings in Fragile X models.Fact-Checked
Mergers & AcquisitionsIncyte, Genmab Partner on KRAS G12D Colorectal Cancer TrialIncyte and Genmab will evaluate petosemtamab, the KRAS G12D inhibitor INCB161734 and chemotherapy in a planned Phase 1/2 study for previously untreated KRAS G12D-mutated metastatic colorectal cancer.Fact-Checked
Mergers & AcquisitionsZymeworks Grants Roche Global Rights to ZW209 in $813M DealZymeworks has granted Roche exclusive global rights to ZW209, an investigational trispecific T-cell engager targeting DLL3-expressing cancers.Fact-Checked
Mergers & AcquisitionsMenarini Bets on Georgiamune’s GIM-621 With $1.1B DealMenarini Group and Stemline Therapeutics have secured exclusive worldwide rights to Georgiamune’s preclinical oral immunotherapy GIM-621 in a deal worth up to $1.1 billion, plus royalties.Fact-Checked
Mergers & AcquisitionsAstraZeneca, Oracle Link Real-World Data With Clinical ResearchAstraZeneca and Oracle Health and Life Sciences have signed a non-binding term sheet to explore AI-enabled clinical trial recruitment, earlier diagnosis and drug-safety monitoring.Fact-Checked
Mergers & AcquisitionsHansoh Expands Roche ADC Deal With $15B+ in Potential MilestonesHansoh Pharma and Roche have expanded their ADC collaboration to cover two preclinical Hansoh programs and multiple additional candidates against Roche-proposed targets.Fact-Checked
Mergers & AcquisitionsAdlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combination TrialAdlai Nortye has partnered with Eli Lilly and Merck KGaA to evaluate AN4035, a novel CEACAM5-targeting ADC with a pan-RAS payload, combined with cetuximab in a Phase I…Fact-Checked
Mergers & AcquisitionsEton Secures U.S. Rights to LIBERVANT Seizure Rescue FilmEton Pharmaceuticals has secured exclusive U.S. commercialization rights to Aquestive Therapeutics’ LIBERVANT (diazepam) buccal film for seizure clusters.Fact-Checked
Mergers & AcquisitionsGenerate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein DrugsGenerate Biomedicines and Zealand Pharma have entered a collaboration to develop AI-designed multispecific protein therapeutics for obesity and other metabolic diseases.Fact-Checked
Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Breast CancerPrelude Therapeutics and Lilly will evaluate PRT13722 with abemaciclib and imlunestrant in a Phase 1 trial for HR+/HER2− breast cancer…Fact-Checked
Mergers & AcquisitionsRoche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity CandidateRoche has secured exclusive worldwide rights to Rona Therapeutics’ investigational ALK7-targeting RNAi candidate in a deal featuring up to $1.16 billion in upfront and potential milestone payments, plus…Fact-Checked
Mergers & AcquisitionsViatris to Acquire Pacira for $1.65 BillionViatris has agreed to acquire Pacira BioSciences for $1.65 billion in an all-cash deal that adds two marketed non-opioid pain therapies, EXPAREL and ZILRETTA, and PCRX-201, an investigational…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.